- eHealth company Respiri (RSH) enters a trading halt ahead of a capital raise
- So far, there is no information on how much the company is aiming to raise or where the funds will be spent
- Under the halt, company shares will be paused until Friday, April 29, or when further details about the raise are released to the market, whichever one comes first
- Last week, Respiri advised the ASX and its shareholders the resignation of Dr Thomas Duthy as Company Director
- RSH shares last traded at 5.1 cents as of April 27
eHealth company Respiri (RSH) has entered a trading halt ahead of a capital raise.
So far, there is no information on how much the company is aiming to raise or where the funds will be spent.
Under the halt, company shares will be paused until Friday, April 29, or when further details about the raise are released to the market, whichever one comes first.
Last week, Respiri advised the ASX and its shareholders the resignation of Dr
Thomas Duthy as Company Director.
Dr Duthy’s decision to step down from his role at Respiri primarily reflects the expansion in executive director responsibilities at an alternate company with the associated increase in that workload and other existing roles.
“It has been an honour to work with the Respiri Board and to serve our shareholders,” Dr Duthy said.
“With favourable unit economics and recurring revenues, overlaid with reimbursement that benefits both the patient and their healthcare providers, wheezo is well-positioned to capitalise on the significant structural trends in respiratory medicine towards connected smart devices providing important patient data to enhance clinical decision making and keeping patients healthier and happier.”
Developed in Australia, the wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions.
RSH shares last traded at 5.1 cents as of April 27.